Citations

Mayo Clinic

Showing 10 of 108585 citations.

Use and continuity of weight‐modifying medications among adults with diabetes and overweight/obesity: US population study
Galindo, Rodolfo J. , Uppal, Tegveer S., McCoy, Rozalina G. , Umpierrez, Guillermo E. , Ali, Mohammed K. , Umpierrez, Guillermo E. , McCoy, Rozalina Grubina , Galindo, Rodolfo J , Ali, Mohammed K

Obesity | November 3, 2023 | Volume: 31 | Issue: 12 | Pages: 2924-2935

10.1002/oby.23869 | PMID 37919239 Get It

AbstractObjectiveTrends in use and continuity of use of diabetes‐specific and non‐diabetes weight‐reducing (WR), weight‐inducing (WI), and weight‐neutral (WN) medications were examined among US adults with diabetes and overweight/obesity.MethodsSerial cross‐sectional data from Medical Expenditure Panel Surveys (2010–2019) for adults (≥18 years) with diabetes and BMI ≥27 kg/m2 (≥25 kg/m2 for Asians) were analyzed.ResultsAmong 7402 US adults with diabetes and overweight/obesity (mean age 60.0 years [SD 13], 50% female), 64.9% of participants used any WI medications, decreasing from 68.9% (95% CI: 64.3%–73.5%) in 2010 to 58.6% (95% CI: 54.7%–62.5%) in 2019. It was estimated that 13.5% used WR medications, increasing 3.31‐fold, from 6.4% (95% CI: 4.1%–8.7%) to 21.2% (95% CI: 18.0%–24.4%) and that 73.1% used WN medications, ranging from 70.5% (95% CI: 66.5–74.6) to 75.0% (95% CI: 71.7%–78.4%). Among adults using diabetes‐specific WI (53.7%), WR (7.1%), and WN (62.4%) medications during the first year, 7.3%, 16.4%, and 9.0% discontinued it in the second year, respectively.ConclusionsOver 2010–2019, 64.9% of adults with diabetes and overweight/obesity were treated with WI medications, 13.5% with WR medications, and 73.1% with WN medications. Discontinuation of WR medications was nearly twice that of WI medications.
Acquired Factor VII Deficiency Associated With Chronic Myeloid Leukemia Blast Crisis
Wolf, Emily, Li, David, Fernandez, Andre, Gardner, Lindsay B., Rivera, Candido E., Wysokinska, Ewa , Shaikh, Marwan , Moustafa, Muhamad Alhaj , Wolf, Emily B , Fernandez, Andre J, Shaikh, Marwan E, Moustafa, Muhamad Alhaj , Tun, Han W. , Roy, Vivek

Journal of Investigative Medicine High Impact Case Reports | November 3, 2023 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23247096231209543 | PMID 37919949 Get It

Factor VII (FVII) is an important, vitamin K-dependent clotting factor. Acquired FVII deficiency is a rare entity that is associated with serious bleeding complications. We report a case of acquired FVII deficiency in a patient with recurrent chronic myeloid leukemia in blast crisis who developed bilateral retinal hemorrhages. The coagulopathy was corrected with the initiation of chemotherapy and subsequent reduction in peripheral blast count.
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Zheng, Jiaying , Wang, Lingxiao , Bosco, Dale B. , Huang, Tao , Dheer, Aastha , Gao, Shan , Xu, Shengze , Ayasoufi, Katayoun , Al‐kharboosh, Rawan , Johnson, Aaron J. , Quiñones‐Hinojosa, Alfredo , Wu, Long‐Jun , Chang, Yuzhou, Ayasoufi, Katayoun , Al-Kharboosh, Rawan, Wu, Long-Jun , Zheng, Jiaying , Zhao, Shunyi , Zhang, Wenjing, Chang, Yuzhou , Qi, Fangfang , Xie, Manling , Johnson, Aaron J. , Dong, Haidong

Neuro-Oncology | November 3, 2023 | Volume: 26 | Issue: 5 | Pages: 811-825

10.1093/neuonc/noad214 | PMID 37941134 Get It

Abstract Background Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. Methods We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both GBM patients and the GL261 mouse glioma model. We utilized multiple mouse glioma models and employed state-of-the-art techniques such as invivo 2-photon imaging, spectrum flow cytometry, and in vitro co-culture assays to study TREM2 function in myeloid cell-mediated phagocytosis of tumor cells, antigen presentation, and response of CD4+ T cells within the tumor hemispheres. Results Our research revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients. TREM2 was predominantly localized in tumor-associated myeloid cells and was highly expressed in nearly all microglia, as well as various subtypes of macrophages. Surprisingly, in preclinical glioma models, TREM2 deficiency did not confer a beneficial effect; instead, it accelerated glioma progression. Through detailed investigations, we determined that TREM2 deficiency impaired the ability of tumor-myeloid cells to phagocytose tumor cells and led to reduced expression of MHCII. This deficiency further significantly decreased the presence of CD4+ T cells within the tumor hemispheres. Conclusions Our study unveiled a previously unrecognized protective role of tumor-myeloid TREM2. Specifically, we found that TREM2 enhances the phagocytosis of tumor cells and promotes an immune response by facilitating MHCII-associated CD4+ T-cell responses against gliomas.
Transarterial Radioembolization: Overview of Radioembolic Devices
Serhal, Muhamad , Gordon, Andrew C. , Toskich, Beau , Lewandowski, Robert J. , Toskich, Beau B. , Brown, Daniel B.

Seminars in Interventional Radiology | November 2, 2023 | Volume: 40 | Issue: 05 | Pages: 461-466

10.1055/s-0043-1772814 | PMID 37927522 Get It

Percutaneous Core Biopsy Devices
Kristeva, Mariya, O’Connor, Stacy D. , Middleton, William D. , Strnad, Benjamin S. , Itani, Malak , Fetzer, David T. , Patel, Maitray D.

Ultrasound Quarterly | November 2, 2023 | Volume: 40 | Issue: 1 | Pages: 1-19

10.1097/ruq.0000000000000664 | PMID 37918119 Get It

Abstract Percutaneous core-needle biopsy (PCNB) plays a growing and essential role in many medical specialties. Proper and effective use of various PCNB devices requires basic understanding of how they function. Current literature lacks a detailed overview and illustration of needle function and design differences, a potentially valuable reference for users ranging from early trainees to experts who are less familiar with certain devices. This pictorial aims to provide such an overview, using diagrams and magnified photographs to illustrate the intricate components of these devices. Following a brief historical review of biopsy needle technology for context, we emphasize distinctions in design between 2 major classes of PCNB devices (side- and end-cutting devices), focusing on practical implications for how each device is most effectively used. We believe a nuanced understanding of biopsy device function sheds light on certain lingering ambiguities in biopsy practice, such as the optimal needle gauge in organ biopsy, the benefits and risks associated with coaxial technique, the impact of needle selection and technique on bleeding, and the risk of unsuccessful sampling. In a subsequent pictorial, we will draw on the concepts presented here to illustrate examples of biopsy needle failure and how unrecognized needle failure can be an important and often preventable cause of increased biopsy risk and lower tissue yield.
Ocular Whipple Disease: Cases Diagnosed Over Four Decades
Salman, Ali R. , Salomão, Diva R. , Olsen, Timothy W. , Smith, Wendy M. , Dalvin, Lauren A.

Ocular Immunology and Inflammation | November 2, 2023 | Volume: 32 | Issue: 8 | Pages: 1863-1868

10.1080/09273948.2023.2271995 | PMID 37917881 Get It

Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, Michael , Acosta, Andrés

British Journal of Pharmacology | November 2, 2023 | Volume: 181 | Issue: 8 | Pages: 1153-1164

10.1111/bph.16278 | PMID 37917871 Get It

The objective is to review the newer pharmacological interventions for obesity, specifically single, dual and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP) and glucagon. There are several approved single or dual incretin agonists which can be administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and other experimental dual or triple incretin agonists. Analogues of amylin, peptide YY and oxyntomodulin, as well as the combination of a GLP1R agonist and GIPR antagonist also are in development. Oral semaglutide (administered daily) is approved for type 2 diabetes mellitus and is on track for regulatory review for obesity. The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying, which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite. In the future, it is anticipated that small molecule GLP‐1 receptor agonists (e.g., oral danuglipron) will be developed for treating obesity. These pharmacological agents are having significant impact on glycaemic control and obesity and on their co‐morbidities.
Invasive Multimodality Neuromonitoring to Manage Cerebral Edema in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Fainberg, Nina, Silver, Maya R. , Arena, John D. , Landzberg, Elizabeth I., Banwell, Brenda , Gambrah-Lyles, Claudia , Madsen, Peter J. , McLendon, Loren , Narula, Sona , Tucker, Alexander M. , Huh, Jimmy W. , Kienzle, Martha , McLendon, Loren A , Landzberg, Elizabeth I. , Kirschen, Matthew P.

Critical Care Explorations | November 2, 2023 | Volume: 5 | Issue: 11 | Pages: e1003

10.1097/cce.0000000000001003 | PMID 37929184 Get It

Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disorder of the CNS with a variety of clinical manifestations, including cerebral edema. Case Summary: A 7-year-old boy presented with headaches, nausea, and somnolence. He was found to have cerebral edema that progressed to brainstem herniation. Invasive multimodality neuromonitoring was initiated to guide management of intracranial hypertension and cerebral hypoxia while he received empiric therapies for neuroinflammation. Workup revealed serum myelin oligodendrocyte glycoprotein antibodies. He survived with a favorable neurologic outcome. Conclusion: We describe a child who presented with cerebral edema and was ultimately diagnosed with MOGAD. Much of his management was guided using data from invasive multimodality neuromonitoring. Invasive multimodality neuromonitoring may have utility in managing life-threatening cerebral edema due to neuroinflammation.
Invited Commentary: Does Field Strength Matter? The Move toward Low-Field-Strength MRI
Venkatesh, Sudhakar K. , McGee, Kiaran P. , Venkatesh, Sudhakar K

RadioGraphics | November 2, 2023 | Volume: 43 | Issue: 12 | Pages: No page available

10.1148/rg.230212 | PMID 37917536 Get It

Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache
Al‐Khazali, Haidar M. , Christensen, Rune H. , Chaudhry, Basit Ali , Ashina, Håkan , Ashina, Håkan , Al-Khazali, Haidar M , Christensen, Rune Häckert , Dodick, David W. , Burstein, Rami

Cephalalgia | November 2, 2023 | Volume: 43 | Issue: 11 | Pages: No page available

10.1177/03331024231210930 | PMID 37917826 Get It

Objective To investigate whether levcromakalim (a K ATP channel opener) induces migraine-like headache in people with persistent post-traumatic headache who had no known history of migraine. Methods In a randomized, double-blind, placebo-controlled, 2-way crossover trial, participants were randomly assigned to receive a 20-minute continuous intravenous infusion of levcromakalim (50 µg/mL) or placebo (isotonic saline) on two separate experimental days with a 1-week wash-out period in between. The primary endpoint was the difference in incidence of migraine-like headache between levcromakalim and placebo during a 12-hour observational period after infusion start. The secondary endpoint was the difference in area under the curve for baseline-corrected median headache intensity scores between levcromakalim and placebo during the 12-hour observational period. Results A total of 21 participants with persistent post-traumatic headache were randomized and completed the trial. During the 12-hour observational period, 12 (57%) of 21 participants reported experiencing migraine-like headache following the levcromakalim infusion, compared with three after placebo ( P = 0.013). Moreover, the baseline-corrected median headache intensity scores were higher following the levcromakalim infusion than after placebo ( P = 0.003). Conclusion Our findings suggest that K ATP channels play an important role in the pathogenesis of migraine-like headache in people with persistent post-traumatic headache. This implies that K ATP channel blockers might represent a promising avenue for drug development. Further research is warranted to explore the potential therapeutic benefits of K ATP channel blockers in managing post-traumatic headache. Trial Registration: ClinicalTrials.gov Identifier: NCT05243953